Tests selinexor with azacitidine after transplant in high-risk blood cancers
Tests selinexor plus azacitidine in people with high-risk myeloid blood cancers after transplant.
Plain-language title generated from the registry record
Registry title: Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Key facts
- Where
- Tianjin, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 16 to 75 with high-risk myeloid blood cancers (AML, MDS or CMML) who are taking maintenance treatment after a transplant.
- Age
- 16 to 75 years
- Sex
- All sexes can join.
- Disease stage
- High-risk MDS, or AML with a high risk of coming back (refractory, relapsed, or MRD-positive before transplant, or poor-prognosis AML), or CMML, or MDS or CMML that has turned into AML.
- Earlier treatment
- The record describes the people as post-transplant. People who relapsed within 3 months of transplantation or during maintenance therapy cannot join.
- Biomarker or test result
- For pre-transplant MRD-positive AML: more than 0.01% abnormal myeloid cells on a pre-transplant flow test, or a positive pre-transplant molecular test.
Main reasons for not taking part
- Relapse within 3 months of transplantation or during maintenance therapy
- Known HIV-positive test, or active hepatitis B or hepatitis C
- Pregnancy, or unable to use proper contraception during treatment
- Suspected allergy to the study drug or any of its ingredients
- Active heart disease, such as a heart attack less than 6 months before entry or uncontrolled heart failure
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 75 years old?
Source: NCT06900088, who can take part
Where in China
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.Tianjin, ChinaContact: Erlie jiangNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT06900088
- Record updated
- 28 March 2025
- Original description
Efficacy and Safety of Selinexor Combined with Azacitidine as Maintenance Therapy in High-Risk Myeloid Neoplasms Patients Post-Transplantation: A Single-Center, Single-Arm, Exploratory StudyRead full original descriptionShow less
Efficacy and Safety of Selinexor Combined With Azacitidine as Maintenance Therapy in High-Risk Myeloid Neoplasms Patients Post-Transplantation: A Single-Center, Single-Arm, Explorato
Efficacy and Safety of Selinexor Combined with Azacitidine as Maintenance Therapy in High-Risk Myeloid Neoplasms Patients Post-Transplantation: A Single-Center, Single-Arm, Exploratory Study
Inclusion: with pre-transplant MRD-positive AML, i.e., patients who meet one of the following criteria:; Age≥ 16 years old; any gender; High-risk MDS (IPSS-R or/and IPSS-M high-risk and above); High relapse risk AML, including relapsed refractory AML and patients with pre-transplant MRD-positive AML, i.e., patients who meet one of the following criteria:; (1)Refractory AML is defined as meeting one of the following conditions; Primary cases that have failed to respond to 2 courses of standard regimen chemotherapy; CR was followed by consolidation and intensive treatment with no recurrence within 12 months; It recurred 12 months later, but conventional chemotherapy was ineffective; 2 or more relapses; Extramedullary leukemia persists. (2)Relapsed AML i.e., re-initialization of leukemic cells in the peripheral blood after complete remission (CR) or bone marrow primitive cells >0.050 (except for other reasons such as bone marrow reconstitution after consolidation chemotherapy) or extramedullary infiltration of leukemic cells; (3)Positive pre-transplant MRD, i.e., one of the following conditions is met:; Proportion of abnormal myeloid cells >0.01% by pre-transplant flow assay; Positive pre-transplantation molecular biology-related tests. (4)AML with poor prognosis (according to the Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Myeloid Leukemia (Non-Acute Promyelocytic Leukemia) 2023 Edition) 4.Meets WHO diagnostic criteria for staging CMML; 5.MDS or CMML transforms AML.
Exclusion: Patients who relapsed within 3 months of transplantation or during maintenance therapy, including hematologic, molecular genetic, cytogenetic relapses, and extramedullary relapses; Known positive serology for HIV or active hepatitis B virus (HBV) and hepatitis C virus (HCV); Requirements for mental illness or other conditions that preclude cooperation with study treatment and monitoring; Suspected hypersensitivity to the experimental drug or any of its excipients; Active heart disease, defined as one or more of the following:; （1）History of uncontrolled or symptomatic angina; （2）Myocardial infarction less than 6 months from study entry; （3）History of tardive dyskinesia requiring medication or clinically significant symptoms; （4）Uncontrolled or symptomatic congestive heart failure (> NYHA class 2) （5）Ejection fraction is below the lower limit of the normal range. 7. Those deemed unsuitable for enrollment by the investigator; Patients with any of the following are not eligible for enrollment in this study:; Patients who are pregnant or who are unable to use appropriate contraception during treatment.